Search hospitals

>

Texas

>

Houston

M D Anderson Cancer Center

Claim this profile

Houston, Texas 77030

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Solid Tumors

Conducts research for Pancreatic Cancer

6030 reported clinical trials

470 medical researchers

Photo of M D Anderson Cancer Center in HoustonPhoto of M D Anderson Cancer Center in Houston

Summary

M D Anderson Cancer Center is a medical facility located in Houston, Texas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Solid Tumors, Pancreatic Cancer and other specialties. M D Anderson Cancer Center is involved with conducting 6,030 clinical trials across 2,169 conditions. There are 470 research doctors associated with this hospital, such as Najat C. Daw, Sarina Piha-Paul, MD, Timothy Yap, and Funda Meric-Bernstam, MD.

Area of expertise

1

Cancer

Global Leader

M D Anderson Cancer Center has run 1217 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 positive
2

Breast Cancer

Global Leader

M D Anderson Cancer Center has run 711 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 negative

Top PIs

Clinical Trials running at M D Anderson Cancer Center

Acute Myeloid Leukemia

Lung Cancer

Myelodysplastic Syndrome

Breast Cancer

Cancer

Acute Myelogenous Leukemia

Non-Hodgkin's Lymphoma

Esophageal Adenocarcinoma

Colorectal Cancer

Chronic Myeloid Leukemia

Image of trial facility.

Venetoclax + Azacitidine

for Acute Myeloid Leukemia

This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem cell transplant may help control high risk leukemia and prevent it from coming back after the transplant.

Recruiting

3 awards

Phase 2

23 criteria

Image of trial facility.

Chemotherapy Combination

for Leukemia

This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and idarubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a antitumor drug, called calicheamicin. Gemtuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD33 receptors, and delivers calicheamicin to kill them. Colony-stimulating factors, such as filgrastim-sndz, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride may kill more cancer cells.

Recruiting

3 awards

Phase 2

Image of trial facility.

Azacitidine + Venetoclax + Gilteritinib

for Leukemia

This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in treating patients with FLT3-mutation positive acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome/myeloproliferative neoplasm that has come back (recurrent) or has not responded to treatment (refractory). Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving azacitidine, venetoclax, and gilteritinib may work better compared to azacitidine and venetoclax alone in treating patients with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndrome/myeloproliferative neoplasm.

Recruiting

3 awards

Phase 1 & 2

10 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at M D Anderson Cancer Center?

Where is M D Anderson Cancer Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does M D Anderson Cancer Center accept?

What awards or recognition has M D Anderson Cancer Center received?